These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32976214)

  • 1. LncRNA CDKN2B-AS1 contributes to tumorigenesis and chemoresistance in pediatric T-cell acute lymphoblastic leukemia through miR-335-3p/TRAF5 axis.
    Chen L; Shi Y; Li J; Yang X; Li R; Zhou X; Zhu L
    Anticancer Drugs; 2020 Sep; ():. PubMed ID: 32976214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA CDKN2B-AS1 promotes the progression of ovarian cancer by miR-143-3p/SMAD3 axis and predicts a poor prognosis.
    Xu C; Zhai J; Fu Y
    Neoplasma; 2020 Jul; 67(4):782-793. PubMed ID: 32305052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNA cyclin-dependent kinase inhibitor 2B antisense ribonucleic acid 1 is associated with in-stent restenosis and promotes human carotid artery smooth muscle cell proliferation and migration by sponging miR-143-3p.
    Ma H; Dong A
    Exp Ther Med; 2021 Mar; 21(3):234. PubMed ID: 33603842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA CDKN2B-AS1 enhances LPS-induced apoptotic and inflammatory damages in human lung epithelial cells via regulating the miR-140-5p/TGFBR2/Smad3 signal network.
    Wang B; Sun Q; Ye W; Li L; Jin P
    BMC Pulm Med; 2021 Jun; 21(1):200. PubMed ID: 34126975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silenced lncRNA DDX11-AS1 or up-regulated microRNA-34a-3p inhibits malignant phenotypes of hepatocellular carcinoma cells via suppression of TRAF5.
    Ding G; Zeng Y; Yang D; Zhang C; Mao C; Xiao E; Kang Y; Shang J
    Cancer Cell Int; 2021 Mar; 21(1):179. PubMed ID: 33752668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retracted Article: LncRNA ZEB2-AS1 regulates the drug resistance of acute myeloid leukemia
    Wang K; Dai J; Liu T; Wang Q; Pang Y
    RSC Adv; 2019 Nov; 9(67):39495-39504. PubMed ID: 35540690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
    Li C; Feng S; Chen L
    Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LNCRNA CDKN2B-AS1 regulates mesangial cell proliferation and extracellular matrix accumulation via miR-424-5p/HMGA2 axis.
    Li Y; Zheng LL; Huang DG; Cao H; Gao YH; Fan ZC
    Biomed Pharmacother; 2020 Jan; 121():109622. PubMed ID: 31707340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulating of cell cycle progression by the lncRNA CDKN2B-AS1/miR-324-5p/ROCK1 axis in laryngeal squamous cell cancer.
    Liu F; Xiao Y; Ma L; Wang J
    Int J Biol Markers; 2020 Mar; 35(1):47-56. PubMed ID: 31960744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA OIP5-AS1 suppresses multiple myeloma progression by sponging miR-27a-3p to activate TSC1 expression.
    Wang Y; Wang H; Ruan J; Zheng W; Yang Z; Pan W
    Cancer Cell Int; 2020; 20():155. PubMed ID: 32410883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulated lncRNA Cyclin-dependent kinase inhibitor 2B antisense RNA 1 induces the proliferation and migration of colorectal cancer by miR-378b/CAPRIN2 axis.
    Zheng Y; Zeng J; Xia H; Wang X; Chen H; Huang L; Zeng C
    Bioengineered; 2021 Dec; 12(1):5476-5490. PubMed ID: 34511033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA CDKN2B-AS1 contributes to glioma development by regulating the miR-199a-5p/DDR1 axis.
    Lu J; Chen Y; Wen L; Zhou Q; Yan S
    J Gene Med; 2022 Jan; 24(1):e3389. PubMed ID: 34559933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retracted Article: LncRNA OIP5-AS1 contributes to ox-LDL-induced inflammation and oxidative stress through regulating the miR-128-3p/CDKN2A axis in macrophages.
    Li X; Cao Q; Wang Y; Wang Y
    RSC Adv; 2019 Dec; 9(71):41709-41719. PubMed ID: 35541591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA CDKN2B-AS1/miR-141/cyclin D network regulates tumor progression and metastasis of renal cell carcinoma.
    Dasgupta P; Kulkarni P; Majid S; Hashimoto Y; Shiina M; Shahryari V; Bhat NS; Tabatabai L; Yamamura S; Saini S; Tanaka Y; Dahiya R
    Cell Death Dis; 2020 Aug; 11(8):660. PubMed ID: 32814766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circ_0010729 regulates hypoxia-induced cardiomyocyte injuries by activating TRAF5 via sponging miR-27a-3p.
    Lei D; Wang Y; Zhang L; Wang Z
    Life Sci; 2020 Dec; 262():118511. PubMed ID: 33010282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDKN2B-AS1 participates in high glucose-induced apoptosis and fibrosis via NOTCH2 through functioning as a miR-98-5p decoy in human podocytes and renal tubular cells.
    Xiao M; Bai S; Chen J; Li Y; Zhang S; Hu Z
    Diabetol Metab Syndr; 2021 Oct; 13(1):107. PubMed ID: 34649592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long Non-Coding RNA OIP5-AS1 Knockdown Enhances CDDP Sensitivity in Osteosarcoma via miR-377-3p/FOSL2 Axis.
    Liu L; Wang S
    Onco Targets Ther; 2020; 13():3853-3866. PubMed ID: 32440152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA CDKN2B-AS1 regulates high glucose-induced human mesangial cell injury via regulating the miR-15b-5p/WNT2B axis.
    Chang J; Yu Y; Fang Z; He H; Wang D; Teng J; Yang L
    Diabetol Metab Syndr; 2020 Dec; 12(1):109. PubMed ID: 33298110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-141-3p and TRAF5 Network Contributes to the Progression of T-Cell Acute Lymphoblastic Leukemia.
    Zhou R; Mo W; Wang S; Zhou W; Chen X; Pan S
    Cell Transplant; 2019 Dec; 28(1_suppl):59S-65S. PubMed ID: 31722554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long Noncoding RNA TP73-AS1 Modulates Medulloblastoma Progression In Vitro And In Vivo By Sponging miR-494-3p And Targeting EIF5A2.
    Li B; Shen M; Yao H; Chen X; Xiao Z
    Onco Targets Ther; 2019; 12():9873-9885. PubMed ID: 31819485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.